Unicycive Therapeutics (UNCY) Receivables - Other (2020 - 2021)

Unicycive Therapeutics' (UNCY) quarterly Receivables - Other came in at $103000.0 in Q3 2021, down 88.57% on a QoQ basis from $901000.0 in Q2 2021.

Unicycive Therapeutics (UNCY) Receivables - Other (2020 - 2021) Analysis & Trends

Unicycive Therapeutics (UNCY) has 2 years of Receivables - Other data on file, last reported at $103000.0 in Q3 2021.

Quarterly Receivables - Other changed N/A year-over-year to $103000.0 in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $103000.0 (changed N/A YoY) and the FY2020 annual result came in at $967000.0, changed N/A from the prior year.
Receivables - Other slipped to $103000.0 in Q3 2021, from $901000.0 in the prior quarter.
In the past five years, Receivables - Other ranged from a high of $967000.0 in Q4 2020 to a low of $103000.0 in Q3 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Unicycive Therapeutics	151.01 Mn	151.01 Mn	-

Download Data